查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1166109

貧血治療藥的全球市場 - 成長，未來展望，競爭分析(2022年～2030年)

Anemia Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

全球貧血治療藥的市場規模，2021年為383億4,520萬美金，從2022年到2030年的預測期間內預計以16.4％的年複合成長率成長。

本報告提供全球貧血治療藥市場相關調查，市場趨勢，競爭資訊，市場區隔分析，新興趨勢，技術分析，企業簡介等資訊。

目錄

第1章 序文

  • 報告的說明
  • 市場區隔
  • 調查手法

第2章 摘要整理

  • 市場概述:全球貧血治療藥市場
  • 全球貧血治療藥市場:各貧血(2021年)
  • 全球貧血治療藥市場:各藥物(2021年)
  • 全球貧血治療藥市場:各地區(2021年)
  • COVID-19影響
  • 富有魅力的投資提案:各地區(2021年)
  • 競爭分析
    • 主要的貧血治療藥市場供應商的市場定位
    • 貧血治療藥市場供應商採用的策略
    • 主要的產業策略

第3章 貧血治療藥市場:商務的預測與市場動態

  • 簡介
  • 全球貧血治療藥市場金額(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素、阻礙因素的影響分析
  • See-Saw分析
  • 波特的五力分析
  • PESTEL分析

第4章 貧血治療藥市場:各貧血(2020年～2030年)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • 缺鐵性貧血
    • 地中海型貧血
    • 再生不良性貧血
    • 溶血性貧血
    • 鐮狀細胞貧血症
    • 惡性貧血

第5章 貧血治療藥市場:各藥物(2020年～2030年)

  • 市場概要
  • 成長和收益分析:2021年對2030年
  • 市場區隔
    • 補充品
    • 抗生素
    • 免疫抑制劑
    • 骨髓刺激劑
    • 皮質類固醇
    • 基因治療
    • 鐵螯合劑

第6章 北美的貧血治療藥市場(2020年～2030年)

  • 市場概要
  • 貧血治療藥市場:各貧血(2020年～2030年)
  • 貧血治療藥市場:各藥物(2020年～2030年)
  • 貧血治療藥市場:各地區(2020年～2030年)
    • 北美

第7章 英國、歐洲聯盟的貧血治療藥市場(2020年～2030年)

  • 市場概要
  • 貧血治療藥市場:各貧血(2020年～2030年)
  • 貧血治療藥市場:各藥物(2020年～2030年)
  • 貧血治療藥市場:各地區(2020年～2030年)
    • 英國、歐洲聯盟

第8章 亞太地區的貧血治療藥市場(2020年～2030年)

  • 市場概要
  • 貧血治療藥市場:各貧血(2020年～2030年)
  • 貧血治療藥市場:各藥物(2020年～2030年)
  • 貧血治療藥市場:各地區(2020年～2030年)
    • 亞太地區

第9章 南美的貧血治療藥市場(2020年～2030年)

  • 市場概要
  • 貧血治療藥市場:各貧血(2020年～2030年)
  • 貧血治療藥市場:各藥物(2020年～2030年)
  • 貧血治療藥市場:各地區(2020年～2030年)
    • 南美

第10章 中東、非洲的貧血治療藥市場(2020年～2030年)

  • 市場概要
  • 貧血治療藥市場:各貧血(2020年～2030年)
  • 貧血治療藥市場:各藥物(2020年～2030年)
  • 貧血治療藥市場:各地區(2020年～2030年)
    • 中東、非洲

第11章 企業簡介

  • Amgen, Inc.
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries, Ltd.
  • AMAG Pharmaceuticals
  • Rockwell Medical
  • Akebia Therapeutics
  • Vifor Pharma Management, Ltd.
  • FibroGen, Inc.
  • GlaxoSmithKline plc
  • Bayer AG
  • Omeros Corporation
  • Merck Sharp & Dohme Corp.
Product Code: 138609-08-22

Industry Outlook

Anemia treatment drugs market accounted for a market value of US$ 38,345.2 Mn in 2021 and projected to grow at a CAGR of 16.4% during the forecast period from 2022 to 2030. An abnormal decrease in the level of red blood cells, irregular red blood cell morphology, or inadequate concentration of haemoglobin in the blood results in anemia. Anemia is caused also due to numerous nutritional and non-nutritional factors such as infectious disease including malaria, soil-transmitted- helminthiasis, hookworm, and tuberculosis). The World Health Organization (WHO) estimated that globally anemia prevalence averaged 56%, with geographical variations in Europe & Asia the prevalence is in a range from 35% to 75%.

"Sickle cell anemia market expected to grow at a significant rate in the coming years due to presence more than five molecules in clinical trials phase III owned by large pharmaceutical companies"

During the forecast period from 2022 to 2030, sickle cell anemia will grow at an exponential rate due to rising prevalence & awareness related to sickle cell anemia, and expected market entry of monoclonal antibodies and other biological drugs to treat sickle cell anemia efficiently. According to World Health Organization (WHO), it is estimated that 312,000 children will be born worldwide with sickle cell anemia annually. Globally, the greatest burden exists in Sub-Saharan Africa, where 75% of the world sickle cell disease occurs. However, the three major molecules targeting sickle cell anemia in clinical trial phase III are Rivipansel (Pfizer, Inc.), Voxelotor (Global Blood Therapeutics, Inc.) and GBT440 (Global Blood Therapeutics, Inc.). Thus, market approval of these drugs in the near future will assist the overall growth of sickle cell anemia treatment market.

"Asia Pacific expected to be the fastest growing region in the global anemia treatment drugs market with highest prevalence of anemic population, and increasing awareness related to the diagnosis & treatment of anemia"

During the forecast period from 2022 to 2030, Asia Pacific expected to grow significantly due to rising prevalence & awareness related to anemia, initiation of anemia awareness campaigns by government & non-government organizations, and developing economic & healthcare infrastructure. According to the Sickle Cell Disease Coalition (SCDC), in 2016 India set a world record for screening 7.5 million people for SCD in a single day with help of effective awareness campaigns carried out by both government & non-government organizations. The key development observed in Asia Pacific was associated with the improvement in screening, interventions, skilled healthcare providers, and accessibility for medicines. The strong drug pipeline for anemia treatment also considered as one of the key factors expected to assist the growth of Asia Pacific anemia treatment drugs market in the near future.

This report further describes the major qualitative assessment factors including key market trends, market drivers & restraints, to assist in better understanding of global anemia treatment drugs market. The major players analyzed based on their product offering, market strategies, recent developments, and business strength. The report also provides attractive investment proposition based on the exhaustive geographical research carried out based on PESTEL analysis. Major companies profiled in the report include Pfizer, Inc., Amgen, Inc., Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Janssen Pharmaceutical, Bayer AG, AMAG Pharmaceuticals, GlaxoSmithKline plc, Akebia Therapeutics, Vifor Pharma Management, Ltd., and FibroGen, Inc. among others.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anemia Treatment Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Anemia Treatment Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Anemia

Iron deficiency anemia

Thalassemia

Aplastic anemia

Hemolytic anemia

Sickle cell anemia

Pernicious anemia

Drug

Supplements

Antibiotics

Immunosuppresants

Bone Marrow Stimulants

Corticosteroids

Gene Therapy

Iron Chelating Agents

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Anemia Treatment Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Anemia Treatment Drugs market?

Which is the largest regional market for Anemia Treatment Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Anemia Treatment Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Anemia Treatment Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Anemia Treatment Drugs Market
  • 2.2. Global Anemia Treatment Drugs Market, By Anemia, 2021 (US$ Million)
  • 2.3. Global Anemia Treatment Drugs Market, By Drug, 2021 (US$ Million)
  • 2.4. Global Anemia Treatment Drugs Market, By Geography, 2021 (US$ Million)
  • 2.5. Impact of Covid 19
  • 2.6. Attractive Investment Proposition by Geography, 2021
  • 2.7. Competitive Analysis
    • 2.7.1. Market Positioning of Key Anemia Treatment Drugs Market Vendors
    • 2.7.2. Strategies Adopted by Anemia Treatment Drugs Market Vendors
    • 2.7.3. Key Industry Strategies

3. Anemia Treatment Drugs Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Anemia Treatment Drugs Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Anemia Treatment Drugs Market: By Anemia, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Iron deficiency anemia
    • 4.3.2. Thalassemia
    • 4.3.3. Aplastic anemia
    • 4.3.4. Hemolytic anemia
    • 4.3.5. Sickle cell anemia
    • 4.3.6. Pernicious anemia

5. Anemia Treatment Drugs Market: By Drug, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Supplements
    • 5.3.2. Antibiotics
    • 5.3.3. Immunosuppresants
    • 5.3.4. Bone Marrow Stimulants
    • 5.3.5. Corticosteroids
    • 5.3.6. Gene Therapy
    • 5.3.7. Iron Chelating Agents

6. North America Anemia Treatment Drugs Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Anemia Treatment Drugs Market: By Anemia, 2020-2030, USD (Million)
  • 6.3. Anemia Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
  • 6.4.Anemia Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 6.4.1.North America
      • 6.4.1.1. U.S.
      • 6.4.1.2. Canada
      • 6.4.1.3. Rest of North America

7. UK and European Union Anemia Treatment Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Anemia Treatment Drugs Market: By Anemia, 2020-2030, USD (Million)
  • 7.3. Anemia Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
  • 7.4.Anemia Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.UK and European Union
      • 7.4.1.1. UK
      • 7.4.1.2. Germany
      • 7.4.1.3. Spain
      • 7.4.1.4. Italy
      • 7.4.1.5. France
      • 7.4.1.6. Rest of Europe

8. Asia Pacific Anemia Treatment Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Anemia Treatment Drugs Market: By Anemia, 2020-2030, USD (Million)
  • 8.3. Anemia Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
  • 8.4.Anemia Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.Asia Pacific
      • 8.4.1.1. China
      • 8.4.1.2. Japan
      • 8.4.1.3. India
      • 8.4.1.4. Australia
      • 8.4.1.5. South Korea
      • 8.4.1.6. Rest of Asia Pacific

9. Latin America Anemia Treatment Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Anemia Treatment Drugs Market: By Anemia, 2020-2030, USD (Million)
  • 9.3. Anemia Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
  • 9.4.Anemia Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Latin America
      • 9.4.1.1. Brazil
      • 9.4.1.2. Mexico
      • 9.4.1.3. Rest of Latin America

10. Middle East and Africa Anemia Treatment Drugs Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Anemia Treatment Drugs Market: By Anemia, 2020-2030, USD (Million)
  • 10.3. Anemia Treatment Drugs Market: By Drug, 2020-2030, USD (Million)
  • 10.4.Anemia Treatment Drugs Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Middle East and Africa
      • 10.4.1.1. GCC
      • 10.4.1.2. Africa
      • 10.4.1.3. Rest of Middle East and Africa

11. Company Profile

  • 11.1. Amgen, Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Hoffmann-La Roche Ltd.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Novartis AG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Pfizer, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Janssen Pharmaceuticals, Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Teva Pharmaceutical Industries, Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. AMAG Pharmaceuticals
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Rockwell Medical
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Akebia Therapeutics
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Vifor Pharma Management, Ltd.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives
  • 11.11. FibroGen, Inc.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Portfolio
    • 11.11.4. Strategic Initiatives
  • 11.12. GlaxoSmithKline plc
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Portfolio
    • 11.12.4. Strategic Initiatives
  • 11.13. Bayer AG
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Portfolio
    • 11.13.4. Strategic Initiatives
  • 11.14. Omeros Corporation
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Portfolio
    • 11.14.4. Strategic Initiatives
  • 11.15. Merck Sharp & Dohme Corp.
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Portfolio
    • 11.15.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Anemia Treatment Drugs Market By Anemia, 2020-2030, USD (Million)
  • TABLE 2 Global Anemia Treatment Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 3 North America Anemia Treatment Drugs Market By Anemia, 2020-2030, USD (Million)
  • TABLE 4 North America Anemia Treatment Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 5 UK and European Union Anemia Treatment Drugs Market By Anemia, 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Anemia Treatment Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 7 Asia Pacific Anemia Treatment Drugs Market By Anemia, 2020-2030, USD (Million)
  • TABLE 8 Asia Pacific Anemia Treatment Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 9 Latin America Anemia Treatment Drugs Market By Anemia, 2020-2030, USD (Million)
  • TABLE 10 Latin America Anemia Treatment Drugs Market By Drug, 2020-2030, USD (Million)
  • TABLE 11 Middle East and Africa Anemia Treatment Drugs Market By Anemia, 2020-2030, USD (Million)
  • TABLE 12 Middle East and Africa Anemia Treatment Drugs Market By Drug, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Anemia Treatment Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Anemia Treatment Drugs Market: Quality Assurance
  • FIG. 5 Global Anemia Treatment Drugs Market, By Anemia, 2021
  • FIG. 6 Global Anemia Treatment Drugs Market, By Drug, 2021
  • FIG. 7 Global Anemia Treatment Drugs Market, By Geography, 2021
  • FIG. 8 Global Anemia Treatment Drugs Market, By Anemia, 2021 Vs 2030, %
  • FIG. 9 Global Anemia Treatment Drugs Market, By Drug, 2021 Vs 2030, %
  • FIG. 10 U.S. Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 11 Canada Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 12 Rest of North America Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 13 UK Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 Germany Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 Spain Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 Italy Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 France Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 Rest of Europe Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 China Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 Japan Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 India Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 Australia Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 South Korea Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 Rest of Asia Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Brazil Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 Mexico Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Latin America Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 GCC Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 29 Africa Anemia Treatment Drugs Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Middle East and Africa Anemia Treatment Drugs Market (US$ Million), 2020 - 2030